A literature review was conducted to ascertain the prognosis of patients with haematological malignancies admitted to the intensive care unit (ICU) and to identify any factors that could be shown to influence outcome. Studies that examined outcomes among patients with haematological malignancy admitted to ICU were evaluated. Pooled outcome data relating to ICU, hospital and six-month mortality were compiled. A qualitative assessment of the evidence relating to putative determinants of prognosis was made. Observational studies examining outcomes among over 10,000 haematological malignancy patients admitted to the ICU were identified. Approximately 40% of such patients survived until hospital discharge. The principle determinants of short-term survival would appear to be related to the severity of the acute illness and the consequent physiological derangement or organ system dysfunction. In the longer term, factors relating to the prognosis of the underlying malignancy appear to be important.
Introduction
Approximately 7% of patients with haematological malignancies who are admitted to hospital become critically ill 1 and roughly half of these require admission to the ICU. This figure is higher among patients undergoing haematopoietic stem cell transplantation (HSCT), where between 11% and 40% of patients develop the need for ICU admission. 2 The prognosis of these patients has historically been regarded as poor. This view is based on numerous case series reporting poor outcomes, which are well described by Silfvast et al. 3 More recently, there have been a number of papers published suggesting that the prognosis of haematological malignancy patients in ICU may have improved over time 4, 5 even among HSCT recipients. 6, 7 If, as has been suggested, there have been improvements in survival, it is also important to know whether these have been seen across the whole population of haematological malignancy patients, or whether there are perhaps subgroups where the outlook remains poor.
What follows is a review of contemporary literature intended to provide up-to-date information regarding the outcomes among these patients as well as an analysis of the factors that may influence their prognosis.
Methods
This study is principally the work of Dr McDowall and was undertaken as a dissertation for the Diploma of Intensive Care Medicine. Dr Cadamy supervised the design and methodology of the study during its preparation as a dissertation. Dr Hart provided input with regards to the haematological aspects of the study design. All three authors then contributed to the preparation of the revised drafts for publication.
The Medline, Embase and Cochrane databases, together with the on-line archive of the Journal of the Intensive Care Society were searched using strategy developed in conjunction with a specialist librarian, with the aim of maximising sensitivity. The most recent search was conducted on the 14th November 2009.
The relevant studies were assessed in terms of their quality by one of the authors (KM). It was necessary to devise a customised quality rating scale as no suitable instrument could be identified. This incorporated elements of the Newcastle-Ottawa Scale 8 and advice published by Altman and others. 9, 10 It is shown in Table 1 . Studies were classified according to the lowest rating they received in any of the domains detailed in Table 1 . Studies that were rated as being of 'low' quality as judged by this scale were not included further in any section of this review.
It was necessary to exclude data from certain studies because it was noted that some institutions had contributed data to multiple studies that contained populations of patients that were not mutually exclusive.
A number of studies that contained a mixed population suffering from both solid organ and haematological malignancies were identified. If separate information regarding the outcomes of the haematology patients was provided, these data were included in the analysis. If this information was not provided in the initial publication, the authors were contacted for further information. However, if such information was not available, then the study was excluded.
An exception was made in the case of HSCT patients, as much of the morbidity stems from treatment-related toxicity and complications, rather than the underlying disease. 2, 11 Therefore, excluding these studies would lead to an unnecessary loss of potentially useful data. This view is supported by the fact that two systematic reviews of this area found no evidence that the indication for transplantation affected outcome in this population. 12, 13 Summary statistics using pooled data from all relevant studies were produced for ICU, hospital and 6-month mortality, showing the proportion of patients surviving at each end-point using Microsoft Excel (Microsoft Corporation Redmond, WA, USA). This process was conducted for all haematological malignancy patients and for those who had undergone HSCT.
Factors impacting prognosis
Many studies were identified which sought to identify factors that could be used to predict outcomes among this patient population. Only studies where the analysis focused exclusively on haematological malignancy patients were considered. A qualitative summary of the evidence in this section is presented due to differences between putative risk factors, outcome measures and statistical methods used by different authors.
Results
The results of the literature searches are shown in Figure 1 . Of the 76 studies identified, 14 were considered to be of low quality in terms of their ability to address the question of prognosis in this patient population. Fifty-five studies were considered to be of moderate quality 1,3,4,6,14-67 and the remaining five were found to be of high quality. 12, [68] [69] [70] [71] There was a wide variation in the survival rates of patients with haematological malignancy admitted to ICU. However, it would appear, based on the results of the largest and best-conducted studies examining outcomes in this population, that approximately 40% of patients will survive until hospital discharge.
There are fewer data relating to longer-term outcomes, but on the basis of the available evidence, approximately 20% of such patients will be alive at six months.
For patients who have undergone any form of HSCT, it would appear that survival rate is lower. The data regarding outcomes in this population are less robust. Short-term survival was estimated at approximately 29%. Longer-term survival was estimated at around 15%.
The proportions of patients surviving at various time points are shown in Table 2 
Follow-up
Complete and of adequate duration Incomplete follow-up, but with evidence to Incomplete follow-up with no evidence to capture outcome data. suggest no differences between those about nature of those patients lost completing study and those lost to follow-up. to follow-up. Numbers lost to follow Numbers lost to follow-up only a minor up constitute a significant-proportion of proportion of the total sample size and are the total sample and would therefore unlikely to have the potential to substantially have the potential to substantially alter alter the results.
results. Table 1 Rating scale used for the assessment of study quality.
Factors affecting prognosis
Studies identified during the search process attempting to define prognostic factors that affected the outcome, in terms of survival of haematological malignancy patients admitted to ICU, were reviewed. Details of all the relevant studies are given in Table 3 .
Unfortunately the majority of studies were small, with potential weaknesses in the statistical methodology that threaten the reproducibility of the conclusions reached. A small number of studies where the methodology used in attempting to define the risk factors associated with outcome appeared more robust were identified. These are considered in greater detail.
The study by Bach et al 12 was well conducted, but applied to a specific population. It involved a systematic review of the literature in order to identify potential risk factors associated with poor outcome among HSCT patients requiring mechanical ventilation and then sought to validate these findings among a prospectively-recruited cohort in a multicentre study. They found that, as in an earlier study by Rubenfeld and Crawford 72 , the combination of hepatic and renal dysfunction in this population carried a particularly poor prognosis, with a post-test probability of mortality of 98-100%.
The study by Verplancke et al 66 looked at a more general population of haematological malignancy patients admitted to ICU and focused on evaluating new statistical methods for determining risk factors. The authors generated four different models for predicting outcome. The prognostic variables identified differed slightly, depending on the model employed. The need for ventilation and having undergone HSCT were associated with a poor outcome in all models. The area under the receiver operating characteristic curve (AUROC) for the models produced, varied from 0.74 to 0.81, suggesting moderate to good discrimination. The presence of bacterial infection was consistently protective. In the multiple logistic regression models, active disease was also associated with a poor outcome. The other variables associated with poor outcome reflected severity of illness and included Acute Physiology and Chronic Health Evaluation (APACHE) II score and various laboratory parameters.
Hampshire et al 29 used the Intensive Care National Audit and Research Council (ICNARC) database to evaluate the performance of various severity of illness scores among ICU patients with haematological malignancy. It was found that the greater the magnitude of physiological derangement, the worse the prognosis. There were some additional factors shown to adversely affect short-term prognosis, which comprised increasing age and malignancy-related factors, including receipt of a bone marrow transplant (BMT) and surprisingly, an underlying diagnosis of Hodgkin' s lymphoma.
In addition to the above studies, there were two others that included a relatively large population of general haematological malignancy patients and appeared relatively well-designed. 39, 68 In both studies, increasing levels of organ system support were associated with worse outcomes.
On the basis of the above studies, it would appear that
Review articles
Studies with appropriate outcome data available 76
Full text articles reviewed 264
Potentially relevant studies considered for inclusion 93
Studies identified from literature search 8109
Additional studies identified from references 11
Abstracts reviewed 377
Duplicates, wrong population or narrative reviews etc 7,473
As above, not identified on screening of abstract 171
Excluded due to lack of outcome data for haematologic malignancy patients or due to overlap with other studies 13 Figure 1 Results of literature search. short-term outcomes among patients with haematological malignancy on ICU are most consistently predicted by the severity of the acute illness, whether this is measured by derangement of individual physiological parameters, composite scores, or increasing levels of organ system failure and support. Some malignancy-related factors such as having undergone a BMT or HSCT are also likely to be important.
In terms of identifying factors associated with longer-term outcomes there were relatively few studies that sought to address this question. Those that did include studies by 37, 42, 48, 62 Perhaps unsurprisingly, factors associated with the malignancy, such as poor risk cytogenetics or a lack of complete remission, are important at later end points, although not necessarily in determining ICU outcomes. All of these studies suffered from the drawbacks of being relatively small and there was no attempt to validate the statistical findings in any of them. For these reasons, although the results seem biologically plausible, the evidence to support this finding is less strong.
Review articles

Reference
Population Nature of Risk factors OR/HR/ 95% confidence p-value Evaluation of analysis identified LR interval analysis Afessa 6 All HSCT Multivariate analysis, APACHE III Table 3 Details of studies that sought to identify prognostic factors affecting the population of interest and an evaluation of the analysis conducted.
Key OR/HR/LR -odds ratio, hazard ratio, likelihood ratio. HL -Hosmer-Lemeshow test. CPR -cardiopulmonary resuscitation ALL -acute lymphoblastic leukaemia. PaO 2 :FiO 2 ratio of arterial partial pressure of oxygen to fraction inspired oxygen. GVHD -graft versus host disease. MLR -multiple logistic regression. CRP -C-reactive protein. LODS -logistic organ dysfunction sore. ODIN -Organ dysfunction and/or INfection. ARDS -acute respiratory distress syndrome. HLA -Human leukocyte antigen. Notes: * In these studies the abbreviation BMT was used, although it is possible that this `actually refers to all HSCT patients.
Review articles Discussion
This review has taken a systematic approach to the literature in an attempt to determine the prognosis of all patients with haematological malignancy who require admission to the ICU. Prior to this, there have been systematic reviews looking exclusively at patients undergoing HSCT that required ICU care 12, 13 and a number of reviews examining outcomes among cancer patients admitted to the ICU, where the haematological malignancy patients only constituted a subgroup. 5, 73 There are strong theoretical grounds for viewing haematological malignancy patients as clinically distinct from those with solid organ tumours. Firstly, there are demographic differences. 74 Secondly, due to the nature of the treatments employed, these patients are rendered pancytopenic for relatively prolonged periods and experience greater overall treatment-related toxicity than is generally seen in the treatment of solid organ tumours. 75, 76 There is some evidence to support the above theoretical view 61, 69, 71, 77 that having haematological as opposed to a solid organ malignancy is associated with worse outcomes. There have been studies that failed to demonstrate a difference between these two groups, but they were small in comparison to the above papers. 5 On this basis, it is felt the decision to focus on patients with haematological malignancy is justified and that this study therefore provides an important addition to the literature concerning this patient population.
Other strengths of this review include the comprehensive nature of the search strategy and the attempts to obtain additional information from authors in order to ensure the inclusion of as much relevant data as possible. There may have been additional unpublished data collected as part of national or institutional databases. However, outcome data from both the ICNARC and the equivalent Scottish databases have recently been published and are included in this review. 29, 68 This review therefore provides a relatively complete picture from the UK. It is interesting to note that the survival rates reported in a large study based on data collected for a Parisian database were similar, 39 suggesting that this study provides an accurate estimate of ICU outcomes for these patients in developed countries. This figure may differ in resource-poor settings.
One important caveat in this review is that the studies were selected for inclusion and reviewed by a single author. A number of measures were employed in order to mitigate the risks. Firstly, the results at every stage of the search process were double-checked. Secondly, in order to reduce selection bias a rating scale was developed to provide objective criteria against which the quality of studies could be assessed for inclusion.
In attempting to identify prognostic factors that were useful in predicting outcomes in this population, it became apparent that there were few high-quality studies in this area, and that more research is required.
In conclusion, this review has provided a comprehensive assessment and summary of the data relating to ICU outcomes in patients with haematological malignancy and has been able to show that these patients now have a reasonable chance of surviving until hospital discharge. However, although it has been possible to identify some prognostic indicators more work is needed in this area.
